Treating Diseases with Pathologies Promoted by Angiogensis

SLU ID 11-034 | Beta amino acid derivatives as integrin antagonists

Background

Integrins which have been shown to have a role in promoting angiogenesis include, αvβ3, αvβ5, and α5β1. Antagonists of RGD-binding integrins should be useful for treatment of human diseases having angiogenesis or fibrosis as a principal part of their pathology.

Overview

Researchers at Saint Louis University have developed novel integrin receptor antagonists, pharmaceutical compositions, and methods for their manufacture and use.

Benefits

The potential benefits of this technology include:

• Increasing the potency of anti-angiogenic activity

• Increasing the possible routes for administering treatments

• Minimizing the production costs for treatments

• Minimizing the storage costs for treatments

Applications

The potential applications of this technology include:

• treating human diseases that have angiogenesis as a principal part of their pathology

Opportunity

Saint Louis University is seeking a partner to further develop and commercialize this technology.